Fiera Capital Corp Takes Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Fiera Capital Corp purchased a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the second quarter, Holdings Channel.com reports. The firm purchased 20,912 shares of the company’s stock, valued at approximately $5,062,000.

Several other hedge funds and other institutional investors have also modified their holdings of ONC. Caitong International Asset Management Co. Ltd purchased a new position in BeOne Medicines in the second quarter valued at about $28,000. Farther Finance Advisors LLC bought a new position in BeOne Medicines during the second quarter valued at approximately $39,000. Signaturefd LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter worth $49,000. Parallel Advisors LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter worth $59,000. Finally, FNY Investment Advisers LLC bought a new position in shares of BeOne Medicines during the 2nd quarter valued at $121,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on ONC shares. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. Guggenheim lifted their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Finally, Citizens Jmp boosted their price objective on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $357.33.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $365.82 on Friday. The firm’s 50-day moving average is $329.90 and its 200-day moving average is $291.46. The company has a market cap of $40.12 billion, a price-to-earnings ratio of 717.29 and a beta of 0.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $381.50.

Insider Activity

In other news, SVP Chan Henry Lee sold 10,671 shares of the business’s stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $350.40, for a total transaction of $3,739,118.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John Oyler sold 27,803 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total value of $9,055,715.13. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 73,272 shares of company stock valued at $24,934,995. Corporate insiders own 6.62% of the company’s stock.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.